Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by LRI Investments LLC

LRI Investments LLC grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 18,333.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,212 shares of the medical research company’s stock after acquiring an additional 2,200 shares during the period. LRI Investments LLC’s holdings in Charles River Laboratories International were worth $457,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth about $41,000. VisionPoint Advisory Group LLC lifted its position in shares of Charles River Laboratories International by 45.1% in the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 65 shares in the last quarter. Brown Brothers Harriman & Co. boosted its stake in shares of Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares during the last quarter. Sunbelt Securities Inc. increased its position in shares of Charles River Laboratories International by 1,072.7% during the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock worth $70,000 after purchasing an additional 236 shares in the last quarter. Finally, Concord Wealth Partners raised its stake in Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 203 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Mizuho started coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. UBS Group cut their price objective on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. JPMorgan Chase & Co. cut Charles River Laboratories International from an “overweight” rating to a “neutral” rating and cut their price target for the company from $270.00 to $205.00 in a report on Thursday, August 8th. Finally, Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $231.00.

Charles River Laboratories International Trading Up 2.0 %

NYSE CRL traded up $3.94 on Friday, reaching $205.27. The stock had a trading volume of 595,201 shares, compared to its average volume of 588,516. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The stock has a fifty day moving average price of $212.72 and a two-hundred day moving average price of $230.03. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The firm has a market capitalization of $10.57 billion, a price-to-earnings ratio of 24.15, a P/E/G ratio of 2.32 and a beta of 1.38.

Charles River Laboratories International announced that its Board of Directors has authorized a stock repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).